140 related articles for article (PubMed ID: 7981084)
1. Intracavitary prophylactic treatment with interferon alpha 2b of patients with superficial bladder cancer is associated with a systemic T-cell activation.
Molto L; Alvarez-Mon M; Carballido J; Manzano L; Guillen C; Prieto A; Olivier C; Rodriguez-Zapata M
Br J Cancer; 1994 Dec; 70(6):1247-51. PubMed ID: 7981084
[TBL] [Abstract][Full Text] [Related]
2. Prophylactic intracavitary treatment with interferon alpha increases interferon gamma production by peripheral blood mononuclear cells in patients with superficial transitional cell carcinoma of the bladder.
Moltó L; Carballido J; Manzano L; Reyes E; Olivier C; Alvarez-Mon M
Br J Cancer; 1997; 75(12):1849-53. PubMed ID: 9192993
[TBL] [Abstract][Full Text] [Related]
3. Use of intracavitary interferon-alpha-2b in the prophylactic treatment of patients with superficial bladder cancer.
Moltó L; Alvarez-Mon M; Carballido J; Olivier C; Gimeno F; Manzano L
Cancer; 1995 Jun; 75(11):2720-6. PubMed ID: 7743476
[TBL] [Abstract][Full Text] [Related]
4. Interferon-alpha-2b enhances the natural killer activity of patients with transitional cell carcinoma of the bladder.
Carballido JA; Moltó LM; Manzano L; Olivier C; Salmerón OJ; Alvarez de Mon M
Cancer; 1993 Sep; 72(5):1743-8. PubMed ID: 8348503
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of escalating doses of intravesical interferon alpha-2b in reducing recurrence rate and progression in superficial transitional cell carcinoma.
Giannakopoulos S; Gekas A; Alivizatos G; Sofras F; Becopoulos T; Dimopoulos C
Br J Urol; 1998 Dec; 82(6):829-34. PubMed ID: 9883220
[TBL] [Abstract][Full Text] [Related]
6. [In vivo and vitro effects of interferon-alpha 2b on functional activity of T-lymphocytes from patients with rheumatoid arthritis].
Iarilina AA; Nikonova MF; Litvina MM; Balabanova RM; Iarilin AA
Ter Arkh; 2000; 72(5):9-17. PubMed ID: 11109610
[TBL] [Abstract][Full Text] [Related]
7. Intravesical immunotherapy for superficial bladder cancer.
Said MT; Abomelha MS; Orkubi SA
Saudi Med J; 2002 Dec; 23(12):1458-61. PubMed ID: 12518191
[TBL] [Abstract][Full Text] [Related]
8. T lymphocytes from autoimmune thrombocytopenic purpura show a defective activation and proliferation after cytoplasmic membrane and intracytoplasmic mitogenic signals.
Garcia-Suarez J; Prieto A; Manzano L; Reyes E; Molto L; Alvarez-Mon M
Am J Hematol; 1993 Sep; 44(1):1-8. PubMed ID: 8393613
[TBL] [Abstract][Full Text] [Related]
9. Alpha 2-b interferon and farmarubicin in the prophylaxis of recurrence of superficial transitional cell carcinoma of the urinary bladder.
Cervenakov I; Szoldova K; Mardiak J; Chovan D; Mala M; Slavov D
Bratisl Lek Listy; 2000; 101(6):317-20. PubMed ID: 11039202
[TBL] [Abstract][Full Text] [Related]
10. Clinical studies on cell-mediated immunity in patients with urinary bladder carcinoma: blastogenic response, interleukin-2 production and interferon-gamma production of lymphocytes.
Ikemoto S; Kishimoto T; Wada S; Nishio S; Maekawa M
Br J Urol; 1990 Apr; 65(4):333-8. PubMed ID: 2111194
[TBL] [Abstract][Full Text] [Related]
11. How effective is topical alpha-2b interferon in preventing recurrence of superficial bladder cancer?
Hoeltl W; Hasun R; Albrecht W; Marberger M
Br J Urol; 1991 Nov; 68(5):495-8. PubMed ID: 1747725
[TBL] [Abstract][Full Text] [Related]
12. [Intravesial instillation of recombination interferon-alpha and pirarubicin in the prophylaxis of local recurrence after resection of the superficial bladder cancer].
Deng JH; Bai JL; Zhang SS; Ma PC; Wan JH
Ai Zheng; 2004 Jul; 23(7):839-41. PubMed ID: 15248924
[TBL] [Abstract][Full Text] [Related]
13. Immunomodulatory effect of interferon-alpha 2b on natural killer cells and T lymphocytes from patients with transitional cell carcinoma of the bladder.
Alvarez-Mon M; Moltó LM; Manzano L; Olivier C; Carballido JA
Anticancer Drugs; 1992 May; 3 Suppl 1():5-8. PubMed ID: 1611117
[TBL] [Abstract][Full Text] [Related]
14. Co-administration of intravesical bacillus Calmette-Guérin and interferon α-2B as first line in treating superficial transitional cell carcinoma of the urinary bladder.
Bazarbashi S; Soudy H; Abdelsalam M; Al-Jubran A; Akhtar S; Memon M; Aslam M; Kattan S; Shoukri M
BJU Int; 2011 Oct; 108(7):1115-8. PubMed ID: 21332904
[TBL] [Abstract][Full Text] [Related]
15. Interferon-a2b reduces neo-microvascular density in the 'normal' urothelium adjacent to the tumor after transurethral resection of superficial bladder carcinoma.
Giannopoulos A; Adamakis I; Evangelou K; Giannopoulou M; Zacharatos P; Zsantoulis P; Perunovic B; Athanasiou A; Retalis G; Constandinidis C; Gorgoulis VG
Onkologie; 2003 Apr; 26(2):147-52. PubMed ID: 12771523
[TBL] [Abstract][Full Text] [Related]
16. Correlation between clinical response and urinary interleukin levels using different doses and intravesical administration schedules of interferon-alpha-2b combined with epirubicin: a pilot study.
Serretta V; Corselli G; Piazza B; Lio D; Gervasi F; Salerno S; Pavone-Macaluso M
Urol Res; 1993; 21(5):353-7. PubMed ID: 8279093
[TBL] [Abstract][Full Text] [Related]
17. Chemoimmunotherapy for prophylaxis of recurrence in superficial bladder cancer: interferon-alpha 2b versus interferon-alpha 2b with epirubicin.
Ferrari P; Castagnetti G; Pollastri CA; Ferrari G; Tavoni F; Grassi D
Anticancer Drugs; 1992 May; 3 Suppl 1():25-7. PubMed ID: 1611113
[TBL] [Abstract][Full Text] [Related]
18. Combined low-dose intravesical immunotherapy (BCG + interferon alpha-2b) in the management of superficial transitional cell carcinoma of the urinary bladder: a five-year follow-up.
Mohanty NK; Malhotra V; Nayak RL; Arora RP
J Chemother; 2002 Apr; 14(2):194-7. PubMed ID: 12017377
[TBL] [Abstract][Full Text] [Related]
19. Diminished DNA synthesis in T cells from B chronic lymphocytic leukemia after phytohemagglutinin, anti-CD3, and phorbol myristate acetate mitogenic signals.
Prieto A; Garcia-Suarez J; Reyes E; Lapeña P; Hernandez M; Alvarez-Mon M
Exp Hematol; 1993 Nov; 21(12):1563-9. PubMed ID: 8405237
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant intravesical mitoxantrone versus recombinant interferon-alpha after transurethral resection of superficial bladder cancer: a randomized prospective study.
Papatsoris AG; Deliveliotis C; Giannopoulos A; Dimopoulos C
Urol Int; 2004; 72(4):284-91. PubMed ID: 15153724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
